Paolo Ascierto, ASCO 2018 – Personalised strategies and advances in the treatment of melanoma
Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment.
1. How are personalised strategies impacting the treatment of melanoma? (0:11)
2. What molecular markers have been validated to inform selection of therapy? (1:04)
3. What is the main focus of current research investigating combinations of therapy in melanoma? (2:16)
4. What have been the latest advances in systemic adjuvant treatment of stage II/III melanoma? (4:20)
5. What do you see as the most important advance in melanoma treatment in recent years? (5:35)
Speaker disclosures: Paolo Ascierto has provided an advisory role for BMS, Roche, MSD, Array, Novartis, Amgen, EMD Serono, Pierre-Fabre, Incyte, Genmad, New Link Genetics, Medimmune, AstraZeneca and Sindax. He has also received research funds from BMS, Roche and Array.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Dermatological Cancers
Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
The STARBOARD trial will investigate encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the mechanisms of encorafenib, binimetinib and pembrolizumab, as well as details on the STARBOARD trial. The presentation entitled […]
Ryan Sullivan, AACR 2023: Current therapeutic options for BRAF V600 mutated melanoma
Multiple therapies that have been approved for the treatment of BRAF V600 mutated melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the current treatment paradigm and its limitations. Ryan Sullivan presented an abstract entitled ‘Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + […]
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!